Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – Here’s What Happened

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY – Get Free Report) gapped down before the market opened on Friday . The stock had previously closed at $6.6170, but opened at $6.28. Coloplast A/S shares last traded at $6.33, with a volume of 222,079 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CLPBY shares. The Goldman Sachs Group cut Coloplast A/S from a “hold” rating to a “strong sell” rating in a research report on Tuesday, April 7th. Kepler Capital Markets raised Coloplast A/S to a “strong-buy” rating in a research report on Wednesday. Finally, Sanford C. Bernstein raised Coloplast A/S to a “hold” rating in a research report on Wednesday, January 28th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold”.

Get Coloplast A/S alerts:

Read Our Latest Research Report on CLPBY

Coloplast A/S Stock Performance

The company has a market capitalization of $14.17 billion, a P/E ratio of 44.91, a price-to-earnings-growth ratio of 2.04 and a beta of 0.15. The company has a debt-to-equity ratio of 1.50, a quick ratio of 0.81 and a current ratio of 1.30. The business has a 50 day moving average of $6.61 and a 200-day moving average of $7.83.

Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its earnings results on Tuesday, May 12th. The company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.09 by $0.01. The business had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.11 billion. Coloplast A/S had a return on equity of 31.96% and a net margin of 7.46%. On average, sell-side analysts predict that Coloplast A/S Sponsored ADR will post 0.4 EPS for the current fiscal year.

Coloplast A/S Company Profile

(Get Free Report)

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast’s offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

Featured Articles

• Five stocks we like better than Coloplast A/S
• SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
• CAVA Group’s Stock Looks Delicious After Strong Earnings
• Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
• Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook

Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.